Drugmaker Corcept seeks to bar ex-judge's views in Teva antitrust case
Reuters2026/10/12 16:57By Mike Scarcella
WASHINGTON, Oct 12 (Reuters) - Drugmaker Corcept Therapeutics CORT.O is seeking to exclude testimony from a retired federal appeals court judge supporting Teva Pharmaceuticals TEVA.TA in an antitrust lawsuit, arguing her opinions could sway jurors without shedding light on the facts of the case.
In a filing on Friday in federal court in California, Corcept said consultant and retired judge Kathleen O’Malley of the US Court of Appeals for the Federal Circuit offered no technical expertise and that her presentation of legal opinions was inappropriate.
"Judge O’Malley’s usurpation of the jury is particularly harmful given her position as a former jurist," Corcept said. "It is likely that the jury will not understand she brings no technical expertise in any factual area in the case and give her testimony undue weight, even though her opinions are ultimately just how she thinks the jury should decide."
Teva, Corcept and O’Malley did not immediately respond to requests for comment.
Teva sued Corcept in 2024, claiming it monopolized the market for the drug Korlym to treat the hormonal disorder Cushing's syndrome. The lawsuit said Teva suffered "substantial lost revenue" from its efforts to market a generic version of Korlym, and seeks unspecified monetary damages and a court order stopping Corcept's alleged anti-competitive conduct.
Korlym's active ingredient is mifepristone, the same drug used for medication abortion. Corcept has denied the allegations.
O’Malley submitted a report as an expert for Teva in the case that said Corcept had filed “sham” patent infringement cases. Teva's lawsuit alleges Corcept pursued bogus lawsuits to thwart competition from Teva's generic version of Korlym.
O’Malley served on the Washington, DC-based Federal Circuit from 2010 to 2022. She later worked at law firms Irell and Sullivan & Cromwell before opening her own consulting business that includes appearing as an expert for companies in lawsuits.
Corcept contends O'Malley's expert report offered potential jurors no help understanding the claims in the lawsuit, in the way a doctor might testify about the scope of a claimed invention.
“Instead, Teva has hired a former federal judge to do the jury’s job for it,” Corcept’s lawyers at Quinn Emanuel said.
The case is Teva Pharmaceuticals USA Inc. v. Corcept Therapeutics Inc. et al, US District Court, Northern District of California, No. 5:24-cv-03567-NW.
For Teva: Devora Allon, Kevin Neylan Jr and Michael Shipley of Kirkland & Ellis
For Corcept: Robert Stone, Adam Wolfson and Steig Olson of Quinn Emanuel Urquhart & Sullivan
(Reporting by Mike Scarcella)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Africa’s payment giant backed by SoftBank is rushing to list in the US! Opay (OPAY.US) plans to raise $336 million, with its valuation possibly exceeding $4 billion
The payment platform Opay Ltd., which focuses on the Nigerian market, plans to raise up to 336 million dollars through an initial public offering (IPO).
BMT surges past $0.039, briefly up over 40%

Western Digital (WDC.US) CFO refutes claims of AI demand peaking: No signs of weakening, if it cools down it could help us catch up with the demand gap
Western Digital's CFO expressed strong support for AI storage demand, stating that hyperscale cloud providers are continuously increasing capital expenditures and have engaged in discussions regarding supply needs through 2030 to 2031. Although the company's quarterly results exceeded expectations and profit guidance was raised, capital expenditure more than doubled compared to the same period last year, putting pressure on free cash flow. This has sparked concerns in the market about the sustainability of returns on AI data center investments. The stock closed down by about 3% on Friday.